
Press Release

August 30, 2024

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Selected for Five Inclusions as a Constituent of GPIF-Adopted ESG Indexes

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) announced today that it has been selected for five inclusions in a constituent of the ESG indexes that cover Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

The indexes in which the Company was selected for inclusion as a constituent are the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Nihonkabu ESG Select Leaders Index, the S&P/JPX Carbon Efficient Index, and Morningstar Japan ex-REIT Gender Diversity Tilt Index.

In addition to the above indexes adopted by GPIF, Sumitomo Pharma has been selected for inclusion (as a constituent) in the FTSE4Good Index Series, a leading ESG investment index, for 22 consecutive years since 2003.

Sumitomo Pharma Group defines the practice of its Mission, "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide," that contributes to the realization of a sustainable society and leads to the sustained enhancement of its corporate value as "Sustainability Management." Sumitomo Pharma will continue to promote Sustainability Management.

* For Initiatives of Sustainability Management of Sumitomo Pharma and external evaluation, please visit:

<https://www.sumitomo-pharma.com/sustainability>

Reference

About five indexes in which Sumitomo Pharma was selected for inclusions in a constituent of the ESG indexes adopted by GPIF

■ FTSE Blossom Japan Index

The FTSE Blossom Japan Index is created by the global index provider FTSE Russell (U.K.) to measure the performance of Japanese companies demonstrating strong Environmental, Social and Governance (ESG) practices. Sumitomo Pharma has been continuously included as a constituent in the Index since 2017 when the Index was launched.

■ FTSE Blossom Japan Sector Relative Index

The FTSE Blossom Japan Sector Relative Index is created by the global index

provider FTSE Russell (U.K.) to measure the performance of Japanese companies demonstrating strong Environmental, Social and Governance (ESG) practices in each sector. Sumitomo Pharma has been continuously included as a constituent in the Index since 2022 when the Index was launched.

■ **MSCI Nihonkabu ESG Select Leaders Index**

Among the stocks that make up the MSCI Nihonkabu IMI Index, the MSCI Nihonkabu ESG Select Leaders Index aims to represent the performance of companies that are leading within their GICS® sector groups in terms of ESG evaluations while also meeting certain quality factor criteria. Sumitomo Pharma has been included as a constituent in the index since 2024 when the Index was launched.

■ **S&P/JPX Carbon Efficient Index**

The S&P/JPX Carbon Efficient Index is an ESG index jointly designed by S&P Dow Jones Indices and Japan Exchange Group. This index comprises companies included in the Tokyo Stock Price Index (TOPIX), and the weight of constituent is determined by carbon efficiency (Carbon emissions per unit of revenue) and the disclosure status of environmental information. Sumitomo Pharma has continued to be included in the index in 2024.

■ **Morningstar Japan ex-REIT Gender Diversity Tilt Index**

Built with the data and scoring methodology of Equileap (Netherlands), the Morningstar (U.S.) Gender Diversity Indexes are designed to emphasize the stocks of companies that have strong gender diversity policies embedded in their corporate culture and that ensure equal opportunities to employees, irrespective of their gender. This index was newly adopted by GPIF from March 2023. Sumitomo Pharma has been included in the constituent stocks since its establishment in 2023, and has been certified as the highest “Group 1.”

About FTSE4Good Index Series

The FTSE4Good Index Series is created by the global index provider FTSE Russell (U.K.) to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. Transparent management and clearly-defined ESG criteria make FTSE4Good indexes suitable tools to be used by a wide variety of market participants when creating or assessing sustainable investment products. Sumitomo Pharma has been continuously included as a constituent in the Index series since 2003.

Contact:

Corporate Communications

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp